Facebook Twitter Instagram
    MedicoNOW IncMedicoNOW Inc
    Saturday, January 28
    Facebook Twitter Instagram
    SUBSCRIBE
    • Home
    • Corona
    • Doctors
    • Hospital
    • Medicine
    • Health Care
    • Diet and Fitness
    • MedicoNow
    • Surgical Instruments
    • Contact
    MedicoNOW IncMedicoNOW Inc
    Home»Corona»UK approves COVID-19 drug that appears effective against Omicron
    Corona

    UK approves COVID-19 drug that appears effective against Omicron

    MedicoNow.comBy MedicoNow.comDecember 17, 2021Updated:November 4, 2022No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Reddit WhatsApp Email
    UK approves COVID-19 drug that appears effective against Omicron
    UK approves COVID-19 drug that appears effective against Omicron
    Share
    Facebook Twitter LinkedIn Pinterest WhatsApp Email

    The United Kingdom has approved the use of a drug to treat people at high risk of developing severe COVID-19 symptoms, which the manufacturers say appears to be effective against the new Omicron variant.
    The antibody treatment, sotrovimab, “was found to be safe and effective at reducing the risk of hospitalization and death in people with mild to moderate COVID-19 infection who are at an increased risk of developing severe disease”, the Medicines and Healthcare products Regulatory Agency (MHRA) said in a statement on Thursday.
    A single dose of the drug was found to reduce the risk of hospitalization and death by 79 percent in high-risk adults with symptomatic COVID-19, according to the regulator.
    Following its review, the MHRA recommended sotrovimab, also known under the brand name Xevudy, be used as soon as possible and within five days of the onset of symptoms.
    June Raine, the MHRA’s chief executive, welcomed its addition to the UK’s arsenal for battling the coronavirus pandemic as “yet another therapeutic that has been shown to be effective at protecting those most vulnerable to COVID-19”.
    Last month, the UK became the first country to approve molnupiravir, a potentially game-changing COVID-19 antiviral pill jointly developed by Merck and Ridgeback Biotherapeutics.

    Sotrovimab was developed by GlaxoSmithKline (GSK), a UK-based company, and the US-headquartered Vir Biotechnology.
    It is a monoclonal antibody, a type of protein that attaches to the spike protein of the coronavirus, reducing its ability to enter the body’s cells.
    GSK said on Thursday that lab analysis showed the drug is effective against viruses that were bio-engineered to carry a number of hallmark mutations of the Omicron variant, which is more heavily mutated than previous strains of the coronavirus.
    Preclinical data showed that the drug “retains activity against key mutations of the new Omicron SARS-CoV-2 variant,” the pharmaceutical giant said in a statement.
    Tests are ongoing to confirm the results against all of the Omicron mutations with an update expected by year-end, it added.
    GSK said sotrovimab had also demonstrated “ongoing activity” against all other tested variants of concern and interest identified by the World Health Organization, including the highly transmissible Delta strain which has fuelled a surge in cases in many parts of Europe, the current epicenter of the pandemic, in recent months.
    Treatments to tackle the global health crisis, which has killed more than five million people worldwide, have so far focused mainly on vaccines.

    MedicoNow.com
    • Website

    Related Posts

    Nasal COVID-19 Vaccines – What You Need to Know

    November 27, 2022

    Walk in Covid 19 Vaccination Mainehealth

    October 4, 2022

    Vaccine Passports are Getting a bit Easier to Obtain Heres how to get one afar Media

    October 4, 2022

    Leave A Reply Cancel Reply

    Facebook Twitter Instagram Pinterest
    • Home
    • Corona
    • Doctors
    • Hospital
    • Medicine
    • Health Care
    • Diet and Fitness
    • MedicoNow
    • Surgical Instruments
    • Contact
    Copyright © 2023 Medico NOW LLC | All Rights Reserved | Privacy Policy | Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
    Do not sell my personal information.
    Cookie SettingsAccept
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT